Nafamostat mesylate
Nafamostat mesylate structure
|
Common Name | Nafamostat mesylate | ||
|---|---|---|---|---|
| CAS Number | 82956-11-4 | Molecular Weight | 539.58 | |
| Density | N/A | Boiling Point | 637.2ºCat 760 mmHg | |
| Molecular Formula | C21H25N5O8S2 | Melting Point | 259-261°C | |
| MSDS | Chinese USA | Flash Point | 339.1ºC | |
| Symbol |
GHS08 |
Signal Word | Warning | |
|
A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis.
Clin. Exp. Immunol. 177(2) , 500-8, (2014) While there is evidence of a pathogenic role for complement in inflammatory bowel disease, there is also evidence for a protective role that relates to host defence and protection from endotoxaemia. There is thus concern regarding the use of systemic compleme... |
|
|
Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood.
J. Neuroimmunol. 276(1-2) , 213-8, (2015) Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, characterized by the progressive loss of motor neurons within the central nervous system. Neural degeneration and inflammatory processes, including activation of the complement system a... |
|
|
TMPRSS2, a novel membrane-anchored mediator in cancer pain.
Pain 156 , 923-30, (2015) More than half of all cancer patients have significant pain during the course of their disease. The strategic localization of TMPRSS2, a membrane-bound serine protease, on the cancer cell surface may allow it to mediate signal transduction between the cancer ... |
|
|
Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.
Blood 126 , e1-e10, (2015) Growing interest in natural killer (NK) cell-based therapy for treating human cancer has made it imperative to develop new tools to measure early events in cell death. We recently demonstrated that protease-cleavable luciferase biosensors detect granzyme B an... |
|
|
Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis.
Nat. Commun. 7 , 11037, (2016) Excessive activation of blood coagulation and neutrophil accumulation have been described in several human cancers. However, whether hypercoagulation and neutrophilia are linked and involved in cancer development is currently unknown. Here we show that sponta... |
|
|
Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets.
PLoS ONE 6 , e18812, (2011) The activation of complement during platelet activation is incompletely understood.We sought to explore the formation of C5b-9 and anaphylatoxins binding to collagen-activated platelets.C5b-9, anaphylatoxins C3a, C4a and C5a, and anaphylatoxin receptors C3aR1... |
|
|
Complement drives Th17 cell differentiation and triggers autoimmune arthritis.
J. Exp. Med. 207 , 1135-43, (2010) Activation of serum complement triggers Th17 cell-dependent spontaneous autoimmune disease in an animal model. In genetically autoimmune-prone SKG mice, administration of mannan or beta-glucan, both of which activate serum complement, evoked Th17 cell-mediate... |
|
|
Rapid-onset clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced arthritis model.
Clin. Exp. Immunol. 177(1) , 219-33, (2014) Preclinical evidence supports targeting the C5a receptor (C5aR) in rheumatoid arthritis (RA). To support ongoing clinical development of an anti-C5aR monoclonal antibody, we have investigated for the first time the mechanism of action and the pharmacodynamics... |